Key result
Thrombolytic therapy with recombinant tissue-type plasminogen activator (rt-PA) was successfully conducted in two neonates with arterial thromboses.
Case Report (n=2)
Thrombolytic treatment with rt-PA can be successfully used in neonates with arterial thromboses when loss of limbs or organs is imminent.
Compared to children of other age groups neonates show an increased thrombotic risk. The acute therapy depends on thrombus age, the localisation of vascular occlusion and the severity of the underlying disease. The treatment of choice is represented by the administration of unfractionated (UFH) or low molecular weight heparin (LMWH). If loss of limbs or organs is imminent, the application of thrombolytic treatment with recombinant tissue-type plasminogen activator (rt-PA) should be considered whilst taking into account the associated bleeding risk. We report on two patients in which thrombolytic therapy has been conducted successfully.
No takes yet. Share an insight, caveat, or question.
Dinger et al. (2014) conducted a case report in neonatal arterial thromboses (n=2). thrombolytic therapy (recombinant tissue-type plasminogen activator / rt-PA) was evaluated on successful treatment. Thrombolytic therapy with recombinant tissue-type plasminogen activator (rt-PA) was successfully conducted in two neonates with arterial thromboses.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: